The Basics
What is Iothalamate Sodium I 125?
A kidney function diagnostic agent.
Brand names for Iothalamate Sodium I 125
Na
How Iothalamate Sodium I 125 is classified
Radiopharmaceuticals, Iodine Radioisotopes, Diagnostic Agents
Iothalamate Sodium I 125 During Pregnancy
Iothalamate Sodium I 125 pregnancy category
Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Iothalamate Sodium I 125 while pregnant
N/A
Taking Iothalamate Sodium I 125 While Breastfeeding
What are recommendations for lactation if you're taking Iothalamate Sodium I 125?
Information in this record refers to the use of iothalamate sodium I 125 as a kidney function diagnostic agent. No information is available on the use of iothalamate sodium I 125 during breastfeeding. However, the biologic half-life of iothalamate after intravenous administration is 1.5 hours with normal kidney function, so the drug will be almost completely eliminated from the body in 8 hours. This time may be longer in patients with impaired kidney function and in patients who receive the drug by subcutaneous injection.[1] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2][3][4] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]
Maternal / infant drug levels
Information in this record refers to the use of iothalamate sodium I 125 as a kidney function diagnostic agent. No information is available on the use of iothalamate sodium I 125 during breastfeeding. However, the biologic half-life of iothalamate after intravenous administration is 1.5 hours with normal kidney function, so the drug will be almost completely eliminated from the body in 8 hours. This time may be longer in patients with impaired kidney function and in patients who receive the drug by subcutaneous injection.[1] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2][3][4] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[5]
Possible effects of Iothalamate Sodium I 125 on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Iothalamate Sodium I 125
Iodohippurate Sodium I 125.
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Turkel C, Fox A. Hints for successful use of subcutaneous Glofil-125. Nephron. 1998;78:230. PMID: 9496747
2. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PMID: 2645546
3. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.
4. National Radiation Protection Board (UK). Administration of radioactive substances advisory committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2019. https://assets.publishing.service.gov.uk/government/…/file/…/ARSAC_NfG_2019.pdf
5. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
